Harding EK, Zamponi GW. Central and peripheral contributions of T-type calcium channels in pain. Mol Brain. 2022;15:39.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bourinet E, Alloui A, Monteil A, Barrère C, Couette B, Poirot O, et al. Silencing of the Cav3.2 T-type calcium channel gene in sensory neurons demonstrates its major role in nociception. EMBO J. 2005;24:315–24.

Article  CAS  PubMed  Google Scholar 

François A, Schüetter N, Laffray S, Sanguesa J, Pizzoccaro A, Dubel S, et al. The low-threshold calcium channel Cav3.2 determines low-threshold mechanoreceptor function. Cell Rep. 2015;10:370–82.

Article  PubMed  Google Scholar 

Snutch T, Zamponi GW. Recent advances in the development of T-type calcium channel blockers for pain intervention. Br J Pharmacol. 2018;175:2375–83.

Article  CAS  PubMed  Google Scholar 

Chemin J, Monteil A, Perez-Reyes E, Nargeot J, Lory P. Direct inhibition of T-type calcium channels by the endogenous cannabinoid anandamide. EMBO J. 2001;20:7033–40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gadotti VM, Huang S, Zamponi GW. The terpenes camphene and alpha-bisabolol inhibit inflammatory and neuropathic pain via Cav3.2 T-type calcium channels. Mol Brain. 2021;14:166.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ross HR, Napier I, Connor M. Inhibition of recombinant human T-type calcium channels by Delta9-tetrahydrocannabinol and cannabidiol. J Biol Chem. 2008;283:16124–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Harding EK, Souza IA, Gandini MA, Gadotti VM, Ali MY, Huang S, et al. Differential regulation of Cav 3.2 and Cav 2.2 calcium channels by CB1 receptors and cannabidiol. Br J Pharmacol. 2023. https://doi.org/10.1111/bph.16035.

Article  PubMed  Google Scholar 

Casey SL, Mitchell VA, Sokolaj EE, Winters BL, Vaughan CW. Intrathecal actions of the cannabis constituents Δ(9)-Tetrahydrocannabinol and cannabidiol in a mouse neuropathic pain model. Int J Mol Sci. 2022;23(15):8649.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang XF, Galaj E, Bi GH, Zhang C, He Y, Zhan J, et al. Different receptor mechanisms underlying phytocannabinoid- versus synthetic cannabinoid-induced tetrad effects: Opposite roles of CB1 /CB2 versus GPR55 receptors. Br J Pharmacol. 2020;177:1865–80.

Article  CAS  PubMed  PubMed Central  Google Scholar 

García-Caballero A, Gadotti VM, Stemkowski P, Weiss N, Souza IA, Hodgkinson V, et al. The deubiquitinating enzyme USP5 modulates neuropathic and inflammatory pain by enhancing Cav3.2 channel activity. Neuron. 2014;83(5):1144–58.

Article  PubMed  Google Scholar 

Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. Brit J Pharmacol. 2008;153:199–215.

Article  CAS  Google Scholar 

Elikottil J, Guopota P, Gupta K. The analgesic potential of cannabinoids. J Opioid Manag. 2009;5:341–57.

Article  PubMed Central  Google Scholar 

Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci U S A. 1999;96:5780–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gadotti VM, You H, Petrov RR, Berger ND, Diaz P, Zamponi GW. Analgesic effect of a mixed T-type channel inhibitor/CB2 receptor agonist. Mol Pain. 2013;9:32.

Article  CAS  PubMed  PubMed Central  Google Scholar